Ginkgo Bioworks posts fall in Q4 revenue; co to divest biosecurity business

Ginkgo Bioworks Holdings

26/02/2026 21:36

Overview

Biotech toolmaker's Q4 revenue fell 24% yr/yr, with adjusted EBITDA improving

Company to divest biosecurity business, focusing on autonomous labs

Company plans to invest in autonomous labs, expanding Boston facility

Outlook

Ginkgo expects total cash burn of $(150)-$(125) million in 2026

Company focuses on autonomous labs as core platform for biotechnology research

Ginkgo plans to complete biosecurity business divestiture in first half of 2026

Result Drivers

CELL ENGINEERING DECLINE - Q4 Cell Engineering revenue decreased 26% due to ongoing program rationalization as part of restructuring activities

Company press release: ID:nPn4RtdMka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$81 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 4.1% below its February 25 closing price of $9.38

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)